Researchers from Généthon (Evry) used genetically modified T lymphocytes (FAP-type CAR-T) to improve gene-drug transfers via adeno-associated viruses (AAV) in gene therapy:
- after two injections, these CAR-T cells were found to be capable of reducing the fibrotic phenomena observed in the mouse model of Duchenne muscular dystrophy (DMD),
- they enable the depletion of progenitor cells with high fibro-adipogenic potential from the muscle,
- when applied in gene transfer protocols in this same model, gene therapy was improved.
This work illustrates the growing interaction between cell therapy and gene therapy.
